AbbVie Inc . (NYSE:ABBV), a major player in the pharmaceutical industry, announced today that its third-quarter financial results for 2024 will include an additional pre-tax expense of $82 million due to acquired IPR&D and milestones. This expense is expected to negatively impact both GAAP and non-GAAP diluted earnings per share by $0.04.
The company's financial results for the quarter ending September 30, 2024, are preliminary and subject to completion of their standard closing procedures. AbbVie has emphasized that the final figures could differ from the current estimates.
AbbVie had previously excluded the impact of acquired IPR&D and milestones expenses beyond the second quarter from its adjusted diluted earnings per share guidance for 2024. However, including the third-quarter expense, the company now forecasts a full-year adjusted diluted earnings per share range of $10.67 to $10.87. For the third quarter specifically, the adjusted diluted earnings per share guidance, factoring in the additional expense, is estimated to be between $2.88 and $2.92.
In other recent news, AbbVie has made significant strides in the healthcare sector. The company has submitted a Biologics License Application to the FDA for the approval of Teliso-V, a potential new treatment for a subset of lung cancer patients. Additionally, AbbVie's Parkinson's treatment, tavapadon, has shown positive results in the Phase 3 TEMPO-1 trial, according to BMO Capital Markets. On a similar note, the company's drug, RINVOQ, has demonstrated efficacy in treating moderate-to-severe atopic dermatitis, particularly in the head and neck regions.
Furthermore, AbbVie's ovarian cancer drug, ELAHERE, received a positive opinion from the European Medicines Agency, based on the results of the Phase 3 MIRASOL clinical trial. In terms of shareholder returns, the company has declared a quarterly cash dividend of $1.55 per share.
InvestingPro Insights
AbbVie's financial landscape, as revealed by InvestingPro data, offers additional context to the company's recent announcement. With a substantial market capitalization of $344.72 billion, AbbVie remains a formidable presence in the pharmaceutical sector. The company's revenue for the last twelve months stands at $55.0 billion, reflecting its significant market position despite a slight revenue decline of 1.83% over the same period.
InvestingPro Tips highlight AbbVie's strong dividend profile, noting that the company has raised its dividend for 12 consecutive years. This consistent dividend growth, coupled with a current dividend yield of 3.15%, may appeal to income-focused investors, especially in light of the company's recent earnings guidance adjustment.
Furthermore, AbbVie's stock has shown robust performance, with a 21.23% price total return over the past three months and a 30.6% return year-to-date. This positive momentum aligns with the InvestingPro Tip indicating that AbbVie is trading near its 52-week high, currently at 97.63% of that peak.
For investors seeking a deeper understanding of AbbVie's financial health and market position, InvestingPro offers 13 additional tips, providing a comprehensive analysis to inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.